menu search

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights
Phase I/2a clinical trials initiated: VMT-α-NET for neuroendocrine tumors, and VMT01 for melanoma. Preliminary results from initial cohorts expected by end of 2023. First patient dosed in Phase 1/2a dose escalation trial of VMT01 for treatment of MC1R-positive metastatic melanoma. RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) — Perspective, Therapeutics, Inc. (“Perspective” […] The post Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business... Read More
Posted: Aug 11 2023, 12:00
Author Name: forextv
Views: 022266

Search within

Pages Search Results: